2026 Preliminary Full Year Result (Unaudited)

Results announcement

1


IPERION LIMITED

Results for announcement to the market
Name of issuer Iperion Limited (NZX: IPR)
Reporting Period 12 months to 31 March 2026
Previous Reporting Period 12 months to 31 March 2025
Currency NZD
Amount (000s) Percentage change
Revenue from continuing
operations
$0 0%
Total Revenue $0 0%
Net profit/(loss) from
continuing operations
$(295) (35%)
Total net profit/(loss) $(295) (35%)
Interim/Final Dividend
Amount per Quoted Equity
Security
The company does not propose to pay a dividend at this time.
Imputed amount per Quoted
Equity Security
Not applicable
Record Date Not applicable
Dividend Payment Date Not applicable
Current period Prior comparable period
Net tangible assets per Quoted
Equity Security
$0.0001 $0.0007
A brief explanation of any of
the figures above necessary to
enable the figures to be
understood
Included with this report is the commentary from the Directors and
financial statements for the year ended 31 March 2026.
The financial statements are in the process of being audited.
Authority for this announcement
Name of person authorised to
make this announcement
John Cilliers
Contact person for this
announcement
John Cilliers
Contact phone number +6 27 242 8485
Contact email address john.cilliers@outlook.co.nz
Date of release through MAP 29 May 2026

2

IPERION LIMITED

Preliminary Full Year Result for the Year Ended 31 March 2026.

Dear Shareholders

The Directors of Iperion Limited (“the Company”) are pleased to report its financial results for the
year ended 31 March 2026.

Financial Results
The Company reported a net loss attributable to shareholders of $294,595 for the year. This
compares with a net loss attributable to shareholders of $455,683 for the previous year.

There was no sales income for the year. The improvement in result compared to the previous year is
mainly a result of discount received on the fixed outsourced manufacturing plant fee.

There were no manufacturing plant expenses for the year. The vendor agreed to discount the
$400,000 fixed annual fees for the two financial years ending 31 March 2026 and 31 March 2027 in
recognition of lower than expected production activity and the plant being partially supported by
research grants secured by the operator on the ongoing development in applications for the
Pathoglaze® product.

Administrative expenses for the year were $294,605 decreasing by $23,176 on the prior year.
Expenses remained mostly in line with the previous year, except for higher stock exchange costs and
lower costs on travel in the year.

Operations and Product Development
Work undertaken over the last year has mainly focused on completing the development of
Pathoglaze infused polymer jute bags used for shipping cocoa and coffee beans. This work is being
undertaken in collaboration with a multinational chocolate manufacturer.

The Company continues to work toward securing long term sales agreements. In order to preserve
available cash reserves, Directors agreed to defer payment of 50% of directors fees since January
2026, until the Company achieves sufficient sales to deliver a positive cash flow result.

On behalf of the Directors of Iperion the Company extends its thanks to the shareholders for their
support of the Company.

3



Preliminary Statement of Comprehensive Income
For the year ended 31 March 2026
UnauditedAudited
YearYear
20262025
$$
Interest Income - financial asset at amortised cost10 20,382
Outsourced manufacturing plant expenses- (150,000)
Administrative expenses(294,605) (317,781)
Depreciation, amortisation and impairment- (8,284)
(294,595) (455,683)
Finance costs- -
Loss before income tax(294,595) (455,683)
Income tax expense- -
Net loss for the period attributable to shareholders(294,595) (455,683)
Other comprehensive income- -
(294,595) (455,683)
Loss before interest and tax
Total comprehensive loss for the period attributable to shareholders

4




Preliminary Statement of Financial Position
As at 31 March 2026
Unaudited
Audited
Year
Year
2026
2025
$
$
Assets
Current assets
Cash and cash equivalents
155,492


425,341


GST receivable
1,196


1,384


Income tax receivable (RWT)
7,563


7,563


164,251


434,288


Non-current assets
NZX Deposit
20,000


20,000


20,000


20,000


Total assets
184,251


454,288


Equity and liabilities
Current liabilities
Trade and other payables
130,448


105,890


Total liabilities
130,448


105,890


Equity
Issued capital
5,672,856


5,672,856


Accumulated loss
(5,619,053)


(5,324,458)


Total equity
53,803


348,398


Total equity and liabilities
184,251


454,288

5


Preliminary Statement of Changes in Equity
For the year ended 31 March 2026
Issued
capital
Accumulated
LossTotal equity
$$$
As at 1 April 20255,672,856 (5,324,458) 348,398
Loss for the year- (294,595) (294,595)
Total comprehensive income- (294,595) (294,595)
At 31 March 20265,672,856 (5,619,053) 53,803
As at 1 April 20245,672,856 (4,868,775) 804,081
Loss for the year- (455,683) (455,683)
Total comprehensive income- (455,683) (455,683)
At 31 March 20255,672,856 (5,324,458) 348,398
Unaudited

6



Preliminary Statement of Cash Flows
For the year ended 31 March 2026
Unaudited
Audited
Year
Year
2026
2025
$
$
Operating activities
10


20,382


Payments to suppliers
(270,047)


(454,996)


Net GST refunds (paid)/received
188


(2,709)


Income tax paid
-


(7,563)


Income tax refund received
-


12,030


Net cash ouflows from operating activities
(269,849)


(432,856)


Investing activities
Purchase of intangible assets
-


(8,284)


-


697,834


Net cash inflows from investing activities
-


689,550


Net increase / (decrease) in cash and cash equivalents
(269,849)


256,694


Cash and cash equivalents at beginning of year
425,341


168,647


Cash and cash equivalents at end of year
155,492


425,341


Interest received
Cash received from maturity of term deposit